Aktieanalys

Cantargia Q1 2025: Approaching Crucial TRIFOUR Readout - Redeye

{newsItem.title}

Redeye Publicerad: 14 May 10:32

Q1 was an active quarter for Cantargia. Among other things, positive multiple ascending dose results for CAN10 were presented, pre-clinical data from a new IL1-RAP ADC were presented, and TRIFOUR was fully recruited, with a first ORR readout expected by mid-2025.

Länk till analysen i sin helhet: https://www.redeye.se/research/1108285/cantargia-q1-2025-approaching-crucial-trifour-readout?utm_source=finwire&utm_medium=RSS

Nyheter om Cantargia

Läses av andra just nu

Om aktien Cantargia

Senaste nytt